NCT02987504 is a Phase 1 clinical trial of Samalizumab in Advanced Solid Tumors, sponsored by Alexion Pharmaceuticals, Inc..

Who is sponsoring NCT02987504?

NCT02987504 is sponsored by Alexion Pharmaceuticals, Inc..

What drugs are being tested in NCT02987504?

Interventions in NCT02987504: Samalizumab.

What condition does NCT02987504 study?

NCT02987504 studies Advanced Solid Tumors.

Is NCT02987504 still recruiting?

NCT02987504 is currently terminated. Last updated 18 July 2018.

Last reviewed 2018-07-18 · How we verify

NCT02987504

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Samalizumab in Patients With Advanced Cancer

Terminated Phase 1 Last updated 18 July 2018

What this trial tests

Phase 1 trial testing Samalizumab in Advanced Solid Tumors in 10 participants. Terminated before completion.

Timeline

17 November 2016

Primary endpoint
12 September 2017

27 September 2017

Quick facts

Lead sponsor	Alexion Pharmaceuticals, Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	17 November 2016
Primary completion	12 September 2017
Estimated completion	27 September 2017
Sites	3 locations across United States

Drugs / interventions tested

Samalizumab — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

Alexion Pharmaceuticals, Inc. — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, open-label, dose-escalation, Phase 1 study of intravenous (IV) samalizumab to determine its maximum tolerated dose (MTD), overall safety/tolerability, pharmacokinetic and pharmacodynamic parameters, and efficacy in participants with advanced cancer. The study was terminated for administrative reasons and not due to any safety concerns.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

NK Cell-Based Immune Checkpoint Inhibition.
Khan M, Arooj S, Wang H. · · 2020 · cited 296× · PMID 32117298 · DOI 10.3389/fimmu.2020.00167
The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy.
Neophytou CM, Pierides C, Christodoulou MI, Costeas P, et al · · 2020 · cited 62× · PMID 32656079 · DOI 10.3389/fonc.2020.00899
CD200 and CD200R1 are differentially expressed and have differential prognostic roles in non-small cell lung cancer.
Yoshimura K, Suzuki Y, Inoue Y, Tsuchiya K, et al · · 2020 · cited 24× · PMID 32395395 · DOI 10.1080/2162402x.2020.1746554
Exploring the dual role of B cells in solid tumors: implications for head and neck squamous cell carcinoma.
Bao J, Betzler AC, Hess J, Brunner C. · · 2023 · cited 20× · PMID 37868967 · DOI 10.3389/fimmu.2023.1233085

Verify or expand the search:

Other trials of Samalizumab

Trials testing the same drug.

NCT00648739 — Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM · Phase 1, PHASE2 · terminated

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Alexion Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT06015750 — Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia · Phase 4 · withdrawn
NCT07352423 — Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants · Phase 1 · recruiting
NCT07221838 — A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab · Phase 4 · recruiting
NCT07413250 — Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis o · active not recruiting
NCT07308574 — Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02987504 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alexion Pharmaceuticals, Inc.
Last refreshed: 18 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02987504.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing